Abstract 1194P
Background
Artificial intelligence (AI) based on deep learning and convolutional neural networks (CNN) has been applied to various medical fields. We are developing a novel AI system to support the detection of lung cancer, which will enable physicians to efficiently interpret radiograms and perform diagnosis.
Methods
For training data, we analyzed the image features of 800 chest X-ray images (acquired mainly for lung cancer screening; 400 normal images and 400 abnormal images) from Fukushima Preservative Service Association of Health and 5 000 chest radiographs from the National Institutes of Health (NIH) database. We categorized these data into two groups. Group A included both 800 images and NIH database, and group B included only 800 images. Then, using ImageNet, we used these datasets to develop a proprietary AI algorithm with deep learning and a CNN, and analyzed the statistical accuracy of interpretations of the radiograms. We also demonstrated abnormal shadow in the form of a heat map display on each chest radiograph for easy visualization, and presented the positive probability score as an index value from 0.0 to 1.0 indicating the possibility of lung cancer. The accuracy of our AI system was improved by using technology to account for differences in radiographic apparatus and imaging environments.
Results
Using a positive probability cutoff value of 0.5, our novel AI showed an area under the curve (AUC) of 0.74, sensitivity of 0.75, and specificity of 0.60 for group A, and AUC of 0.79, sensitivity of 0.72, and specificity of 0.74 for group B. The accuracy on both groups was superior to that of radiologists (AUC 0.72), and was also compatible with previous study reports (AUC 0.67-0.78). The number of training data did not make a difference in accuracy. The heat map display was also clearly demonstrated on the monitor screen if a roentgenogram had abnormal shadows.
Conclusions
In this study, we confirmed that our proprietary AI system had a similar accuracy in the interpretation of chest radiographs to that of previous studies and radiologists. However, further research and improvement is needed to verify the accuracy. We are now in the process of performing various types of validation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Grants-in-Aid for Scientific Research in Japan.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
835P - Genetic, epigenetic, and clinical significance of Wilms’ tumor 1 (WT1) gene in acute myeloid leukemia
Presenter: Harsh Goel
Session: Poster session 09
Resources:
Abstract
836P - A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia
Presenter: Harsh Goel
Session: Poster session 09
Resources:
Abstract
837P - Expression analysis, clinical significance and potential function of ALOX5AP in acute myeloid leukemia
Presenter: Harsh Goel
Session: Poster session 09
Resources:
Abstract
838P - Bayesian modeling in the survival analysis of patients with multiple myeloma with emphasis on missing data analysis
Presenter: Nelson Cruz Gutierrez
Session: Poster session 09
839P - Preliminary results from a phase II study of amulirafusp alfa (IMM0306) in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma
Presenter: jianliang yang
Session: Poster session 09
840P - Orelabrutinib-based regimens in chronic lymphocytic leukemia with comorbidities: A real-world study
Presenter: Xun Lai
Session: Poster session 09
841P - Transforming the landscape of pediatric AML treatment: A cutting-edge SCT prognostic model
Presenter: Hua Yang
Session: Poster session 09
Resources:
Abstract
842P - Exploring the association of side-effects with depression in patients with chronic lymphocytic leukemia who have received treatment: An analysis of the lymphoma coalition’s 2022 global patient survey
Presenter: Natacha Bolanos Fernandez
Session: Poster session 09
843P - Challenges and insights in treating Langerhans cell histiocytosis: Persistent mutations and novel therapeutic approaches
Presenter: Marzieh NASHVI
Session: Poster session 09
844TiP - Orelabrutinib combined with rituximab for the treatment of elderly patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL) under the guidance of genetic subtype: A prospective, multicenter, single-arm, response-adaptive clinical study (Origin)
Presenter: Wanzhuo Xie
Session: Poster session 09